Her question, for the time being, can’t be answered.
“I thought: Generally? What does that mean?” Durbin said.
Never read your own press releases full#
“The convalescent sera levels are not being detailed in our data readout, but would be expected in a downstream full data exposition with NIH and its academic collaborators,” Colleen Hussey, the company’s senior manager for corporate communications, said in an email.ĭurbin was struck by the wording of the company’s statement, pointing to this sentence: “The levels of neutralizing antibodies at day 43 were at or above levels generally seen in convalescent sera.” The response: That will be disclosed in an eventual journal article from NIAID, which is part of the National Institutes of Health. STAT asked Moderna for information on the antibody levels it used as a comparator. So though the company said the antibody levels induced by vaccine were as good as those generated by infection, there’s no real way to know what that comparison means. Recovered patients at the other end of the spectrum had really high antibody levels. John “Jack” Rose, a vaccine researcher from Yale University, pointed STAT to a study from China that showed that, among 175 recovered Covid-19 patients studied, 10 had no detectable neutralizing antibodies.
Moderna stated that the antibody levels seen were on a par with - or greater than, in the case of the 100-microgram dose - those seen in people who have recovered from Covid-19 infection.īut studies have shown antibody levels among people who have recovered from the illness vary enormously the range may be influenced by the severity of a person’s disease. There’s no real way to contextualize the findings We don’t know if those antibodies are durable,” said Anna Durbin, a vaccine researcher at Johns Hopkins University. The report of neutralizing antibodies in subjects who were vaccinated comes from blood drawn two weeks after they received their second dose of vaccine. There’s no way to know how durable the response will be And given who is at highest risk from the SARS-CoV-2 coronavirus, protecting older adults is what Covid-19 vaccines need to do. If, by chance, they mostly clustered around the younger end of the age spectrum, you might expect a better response to the vaccine than if they were mostly from the senior end of it.
Never read your own press releases trial#
Separately, while the Phase 1 trial included healthy volunteers ages 18 to 55 years, the exact ages of these eight people are unknown. Moderna disclosed the findings from eight subjects because that’s all it had at that point. Testing for neutralizing antibodies is more time-consuming than other antibody tests and must be done in a biosecurity level 3 laboratory. This doesn’t mean that they didn’t develop neutralizing antibodies. We don’t know results from the other 37 trial participants. Of the two types, these are the ones you’d really want to see. Later, the statement indicated that eight volunteers - four each from the 25-microgram and 100-microgram arms - developed neutralizing antibodies. Exclusive analysis of biotech, pharma, and the life sciences Learn More
0 kommentar(er)
